Genovis AB sues US company for patent infringement
The Board of Directors of Genovis has announced that it has filed a lawsuit against Promega Corporation (“Promega”) for patent infringement regarding one of Promega’s products. The lawsuit includes an injunction to prevent Promega from producing, using, selling or offering for sale the infringing product, as well as damages. The suit was filed in the United State District Court of Delaware.
Genovis develops, produces and markets innovative technologies that facilitate and enable development of new treatment methods, as well as diagnostics for the pharmaceutical industry. The suit relates to Promega’s new product IdeS Protease, which Genovis believes infringes US Patent No. 7.666.582 for which Genovis has an exclusive global license that expires in 2022 and covers Genovis’ product FabRICATOR®. Genovis has not provided any sublicense to Promega.
“Pursuing legal action is time consuming, but at the same time it is important for Genovis to protect the intellectual property that belongs to the company and its shareholders. FabRICATOR® is the first product Genovis launched and has been sold with good growth in the U.S. market since 2009. The product has also helped to create markets for our other product launches to the world’s leading pharmaceutical companies. Genovis has insurance that covers most of the cost of the suit and I would like to point out that the patent infringement only applies to the U.S. market,” says Sarah Fredriksson, CEO of Genovis.
Genovis’ customers include pharmaceutical and biotech companies, academia and regulatory authorities, including the FDA. They all use FabRICATOR to characterize antibody-based drugs. Modern biological pharmaceuticals against diseases such as cancer are frequently made of antibody molecules that require advanced technology to characterize and analyze them. Analysis is an important cornerstone prior to registration with regulatory authorities, as well as for quality control during production of the approved drug. FabRICATOR is extremely fast and accurate, which enables customers to use a new analytical technique that provides reliable, more easily interpreted results. Customers also save time and lower their analysis costs.
For more information, please contact: Sarah Fredriksson, CEO, Genovis AB Tel: 46 (0)46 -101235 firstname.lastname@example.org
Genovis’ business concept is to develop, produce and market innovative technologies that facilitate and enable development of new treatment methods and diagnostics for customers in the medical device and pharmaceutical industries. The Group consists of Genovis AB and the subsidiary GeccoDots AB. Genovis develops and sells unique enzymes in innovative product formats that facilitate development and quality control of and biological drugs. GeccoDots uses nanotechnology to produce a new type of contrast agent that is used in medical imaging.
Genovis shares are listed on NASDAQ OMX First North, and Consensus is Certified Adviser for the Company, t: 46 (0)31-745 50 00